Biopharmaceutical
Iovance Biotherapeutics is a biopharmaceutical company pioneering tumor infiltrating lymphocyte (TIL) therapy, an innovative cell therapy approach for treating cancer. The company harnesses the human immune system's ability to recognize and attack diverse cancer cells in individual patients. Iovance's TIL platform has demonstrated promising clinical data across multiple solid tumors and represents a transformational approach to cancer treatment. The company is committed to continuous innovation in cell therapy, including gene-edited cell therapy options for cancer patients.
Beta · Sourced from candidate reports
Be the first to share your experience with Iovance Biotherapeutics.
Your reply helps other candidates know what to expect.
